Caribou Biosciences (CRBU)
Market Price (4/22/2026): $2.245 | Market Cap: $212.3 MilSector: Health Care | Industry: Biotechnology
Caribou Biosciences (CRBU)
Market Price (4/22/2026): $2.245Market Cap: $212.3 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -53% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -84%, 3Y Excs Rtn is -122% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -136 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1220% Stock price has recently run up significantly12M Rtn12 month market price return is 183% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 114% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -995%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1009% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -74% Key risksCRBU key risks include [1] its history of operating losses and the need for significant additional financing to fund development, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -53% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -84%, 3Y Excs Rtn is -122% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -136 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1220% |
| Stock price has recently run up significantly12M Rtn12 month market price return is 183% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 114% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -995%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1009% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -74% |
| Key risksCRBU key risks include [1] its history of operating losses and the need for significant additional financing to fund development, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for CB-011.
On March 31, 2026, Caribou Biosciences announced that its allogeneic anti-BCMA CAR-T cell therapy, CB-011, received RMAT designation from the U.S. Food and Drug Administration (FDA) for relapsed or refractory multiple myeloma (r/r MM). This designation, which expedites development and review, was based on promising early clinical data from the CaMMouflage Phase 1 trial, showing a 92% overall response rate and 75% complete response or better in 12 BCMA-naïve patients at the recommended dose for expansion.
2. Positive Clinical Data from Lead CAR-T Programs.
In early February 2026, Caribou presented late-breaking clinical and translational data at the 2026 Tandem Meetings for both its vispa-cel (CB-010) ANTLER Phase 1 trial in B-cell non-Hodgkin lymphoma and its CB-011 CaMMouflage Phase 1 trial in multiple myeloma. The company highlighted that vispa-cel demonstrated efficacy and durability comparable to approved autologous CAR-T cell therapies, and CB-011 data correlated CAR-T cell expansion with deep, durable responses.
Show more
Stock Movement Drivers
Fundamental Drivers
The 41.5% change in CRBU stock from 12/31/2025 to 4/21/2026 was primarily driven by a 20.1% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 12312025 | 4212026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.59 | 2.25 | 41.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 9 | 11 | 20.1% |
| P/S Multiple | 16.0 | 19.1 | 19.5% |
| Shares Outstanding (Mil) | 93 | 95 | -1.3% |
| Cumulative Contribution | 41.5% |
Market Drivers
12/31/2025 to 4/21/2026| Return | Correlation | |
|---|---|---|
| CRBU | 41.5% | |
| Market (SPY) | -5.4% | 34.5% |
| Sector (XLV) | -5.7% | 44.4% |
Fundamental Drivers
The -3.4% change in CRBU stock from 9/30/2025 to 4/21/2026 was primarily driven by a -19.8% change in the company's P/S Multiple.| (LTM values as of) | 9302025 | 4212026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.33 | 2.25 | -3.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 9 | 11 | 22.3% |
| P/S Multiple | 23.8 | 19.1 | -19.8% |
| Shares Outstanding (Mil) | 93 | 95 | -1.6% |
| Cumulative Contribution | -3.4% |
Market Drivers
9/30/2025 to 4/21/2026| Return | Correlation | |
|---|---|---|
| CRBU | -3.4% | |
| Market (SPY) | -2.9% | 43.1% |
| Sector (XLV) | 5.3% | 31.8% |
Fundamental Drivers
The 146.4% change in CRBU stock from 3/31/2025 to 4/21/2026 was primarily driven by a 128.9% change in the company's P/S Multiple.| (LTM values as of) | 3312025 | 4212026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.91 | 2.25 | 146.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 10 | 11 | 11.7% |
| P/S Multiple | 8.3 | 19.1 | 128.9% |
| Shares Outstanding (Mil) | 91 | 95 | -3.6% |
| Cumulative Contribution | 146.4% |
Market Drivers
3/31/2025 to 4/21/2026| Return | Correlation | |
|---|---|---|
| CRBU | 146.4% | |
| Market (SPY) | 16.3% | 34.7% |
| Sector (XLV) | 1.3% | 36.2% |
Fundamental Drivers
The -57.6% change in CRBU stock from 3/31/2023 to 4/21/2026 was primarily driven by a -35.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 3312023 | 4212026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.31 | 2.25 | -57.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 14 | 11 | -19.4% |
| P/S Multiple | 23.4 | 19.1 | -18.5% |
| Shares Outstanding (Mil) | 61 | 95 | -35.5% |
| Cumulative Contribution | -57.6% |
Market Drivers
3/31/2023 to 4/21/2026| Return | Correlation | |
|---|---|---|
| CRBU | -57.6% | |
| Market (SPY) | 63.3% | 30.0% |
| Sector (XLV) | 18.0% | 26.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CRBU Return | -8% | -58% | -9% | -72% | 0% | 44% | -86% |
| Peers Return | -8% | -58% | -5% | -46% | 10% | 49% | -68% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 4% | 89% |
Monthly Win Rates [3] | |||||||
| CRBU Win Rate | 17% | 33% | 33% | 33% | 42% | 50% | |
| Peers Win Rate | 40% | 33% | 43% | 33% | 53% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| CRBU Max Drawdown | -11% | -66% | -43% | -73% | -54% | -13% | |
| Peers Max Drawdown | -40% | -63% | -37% | -51% | -37% | -11% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: CRSP, ALLO, EDIT, NTLA, BEAM.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/21/2026 (YTD)
How Low Can It Go
| Event | CRBU | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -88.2% | -25.4% |
| % Gain to Breakeven | 746.1% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to CRSP, ALLO, EDIT, NTLA, BEAM
In The Past
Caribou Biosciences's stock fell -88.2% during the 2022 Inflation Shock from a high on 9/7/2021. A -88.2% loss requires a 746.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Caribou Biosciences (CRBU)
AI Analysis | Feedback
Caribou Biosciences is like:
- CRISPR Therapeutics for 'off-the-shelf' CAR-T cancer treatments.
- Kite Pharma (Gilead) or Novartis for gene-edited, universal CAR-T therapies.
AI Analysis | Feedback
- CB-010: An allogeneic anti-CD19 CAR-T cell therapy in Phase 1 clinical trial for relapsed or refractory B cell non-Hodgkin lymphoma.
- CB-011: An allogeneic anti-BCMA CAR-T cell therapy developed for the treatment of relapsed or refractory multiple myeloma.
- CB-012: An allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia.
- CB-020: An allogeneic CAR-NK cell therapy designed for the treatment of solid tumors.
AI Analysis | Feedback
Caribou Biosciences (CRBU) is a clinical-stage biopharmaceutical company focused on developing allogeneic cell therapies. As a company in the research and development phase, it does not currently have commercial products on the market being sold to traditional customers like individuals or healthcare providers.
Instead, its primary "customer" or revenue-generating relationship comes from its collaboration agreements with larger pharmaceutical companies for the development and potential commercialization of its drug candidates. Based on the provided description, Caribou Biosciences has a significant collaboration with:
- AbbVie Manufacturing Management Unlimited Company (ABBV)
This collaboration focuses on developing CAR-T cell therapies, where AbbVie acts as a partner that may provide funding, milestone payments, and/or royalties, making it the closest entity to a "customer" for Caribou Biosciences in its current stage of operation.
AI Analysis | Feedback
nullAI Analysis | Feedback
Rachel Haurwitz, PhD - President and Chief Executive Officer
Rachel Haurwitz is a co-founder of Caribou Biosciences and has served as its President and Chief Executive Officer and a director since the company's inception in 2011. She is an inventor on patents and patent applications covering multiple CRISPR-based technologies. In 2014, she was named to Forbes Magazine's "30 Under 30" list in Science and Healthcare, and in 2016, Fortune Magazine named her to the "40 Under 40" list of the most influential young people in business. She also co-founded Intellia Therapeutics Inc. and served as a Director there from May 2014 to November 2016.
Sri Ryali - Chief Financial Officer
Sri Ryali was appointed Chief Financial Officer of Caribou Biosciences, effective January 2, 2025. He is responsible for strategic leadership of the company's corporate finance, accounting, investor relations, and corporate communications functions. Prior to joining Caribou, he served as Chief Financial Officer of Codexis, Inc., a publicly traded enzyme engineering company, from January 2023 to October 2024. Previously, he was Chief Financial Officer of Eiger BioPharmaceuticals, Inc., a publicly traded, commercial-stage company, from December 2018 to January 2023. He also held roles of increasing responsibility, most recently as Vice President of Finance, at Aimmune Therapeutics, Inc., a publicly traded biopharmaceutical company that was subsequently acquired by Nestlé Health Science in 2020.
Barbara McClung, JD - Chief Legal Officer and Corporate Secretary
Barbara McClung serves as Chief Legal Officer and Corporate Secretary for Caribou Biosciences, a position she has held since April 2015. She oversees and manages all legal functions, including corporate and board governance, securities reporting, compliance, contracts, corporate transactions, employment law, and intellectual property strategy. Before joining Caribou, she was General Counsel and Corporate Secretary at Intarcia Therapeutics, Inc. and also at Cygnus, Inc. At Cygnus, Inc., she assisted in the negotiation and completion of the sale of the company's glucose monitoring assets to Animas Corporation/Animas Technologies LLC. She began her career as a patent attorney with E. I. du Pont de Nemours and Company, and later served as patent counsel for Chiron Corporation's vaccine division.
Tim Kelly - Chief Technology Officer
Tim Kelly is the Chief Technology Officer of Caribou Biosciences. He is responsible for the company's technical operations strategy and execution. He brings over 25 years of experience in global clinical and commercial product development, manufacturing, and supply chain operations in the biopharmaceutical and cell and gene therapy industries in the US and Europe.
Ruhi Khan - Chief Business Officer
Ruhi Khan serves as Chief Business Officer for Caribou Biosciences. She is responsible for developing and executing the company's business development strategy. She has over 20 years of business development and investment management experience focused on the biotechnology and pharmaceutical industries. Most recently, Ruhi was the founder of an advisory firm providing business development and finance advice to life sciences companies. In this role, she had extensive senior management experience as head of business development for several oncology-focused companies.
AI Analysis | Feedback
Key Risks to Caribou Biosciences (CRBU)
- Clinical Development and Regulatory Approval Risk: As a clinical-stage biopharmaceutical company, Caribou Biosciences faces the inherent and significant risk of its product candidates, such as CB-010, CB-011, CB-012, and CB-020, failing to demonstrate sufficient safety and efficacy in ongoing and future clinical trials. The success of clinical trials is a binary outcome, meaning the drug either works or it does not, and even promising early-phase data may not be predictive of later-stage trial results. Furthermore, obtaining the necessary regulatory approvals from agencies like the FDA is a lengthy, complex, and expensive process with no guarantee of success, and delays or failures in this process could significantly impede the company's ability to bring its therapies to market.
- Financial Health and Funding Risk: Caribou Biosciences has a history of significant operating losses and is expected to continue incurring losses as it advances its product pipeline through clinical development. While the company has extended its cash runway into the second half of 2027, this does not fully cover the substantial capital requirements needed to fund pivotal Phase 3 clinical trials, particularly for vispa-cel (CB-010). The failure to secure additional financing when needed could lead to delays or the inability to complete the development and potential commercialization of its critical product candidates. The company's financial health indicators, including a negative Altman Z-Score, suggest a potential risk of financial distress if funding is not adequately managed.
- Manufacturing and Allogeneic Cell Therapy Specific Challenges: The development and commercialization of allogeneic cell therapies involve complex manufacturing processes that can lead to production interruptions, quality control issues, and reliance on third-party contract manufacturing organizations (CMOs). These complexities can impact the company's ability to conduct clinical trials and, if successful, commercialize its products efficiently. Additionally, allogeneic cell therapies inherently carry the risk of immunological rejection, such as graft-versus-host disease (GVHD), due to differences in human leukocyte antigen (HLA) between donor and recipient. Overcoming these immune barriers often requires sophisticated genetic engineering or immunosuppressant therapies, which can introduce further risks and complexities to treatment efficacy and patient safety.
AI Analysis | Feedback
The emergence and increasing adoption of bispecific antibodies targeting the same antigens and indications as Caribou's lead product candidates. For example, for B cell non-Hodgkin lymphoma (Caribou's CB-010 targeting CD19), approved CD3xCD20 bispecific antibodies (e.g., epcoritamab, glofitamab) offer off-the-shelf treatment options. Similarly, for multiple myeloma (Caribou's CB-011 targeting BCMA), approved CD3xBCMA bispecific antibodies (e.g., teclistamab, elranatamab) provide an alternative. These bispecific antibodies represent a distinct class of immunotherapy that is generally easier to administer and more readily available off-the-shelf compared to cell therapies, potentially reducing the market opportunity for both autologous and allogeneic CAR-T cell therapies by providing effective alternatives with fewer logistical hurdles.AI Analysis | Feedback
```htmlCaribou Biosciences (CRBU) is developing several genome-edited allogeneic cell therapies targeting significant addressable markets:
-
CB-010 for relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL):
- The global B-cell lymphoma market size was valued at USD 5.08 billion in 2024 and is projected to reach USD 10 billion by 2034. North America held the largest share of this market in 2024.
- More specifically, the global non-Hodgkin lymphoma treatment market size was valued at USD 11.59 billion in 2025 and is projected to reach USD 19.44 billion by 2034. B-cell lymphoma is expected to account for a dominant share of this market, at 87.04% in 2026. North America held a market share of 49.35% in 2025.
- For the relapsed or refractory diffuse large B-cell lymphoma (a major subtype of B-NHL), the global market is estimated at USD 1.61 billion in 2025 and is expected to reach USD 2.16 billion in 2032. North America is estimated to hold a dominant position, with 39.1% of the market share in 2025.
-
CB-011 for relapsed or refractory multiple myeloma:
- The global multiple myeloma market size was estimated at USD 24.12 billion in 2025 and is forecast to reach USD 38.09 billion by 2031.
- Another estimate indicates the global multiple myeloma market size was USD 29.24 billion in 2025, projected to reach USD 49.79 billion by 2034. North America dominated this market with a 58.28% share in 2025.
- Specifically for the relapsed and refractory multiple myeloma treatment market, it was valued at US$23.0 billion in 2025 and is expected to reach US$31.5 billion by 2032. Across the top 7 major markets (US, EU4, UK, and Japan), this market reached USD 22.0 billion in 2024 and is expected to reach USD 37.3 billion by 2035.
-
CB-012 for relapsed or refractory acute myeloid leukemia:
- The global acute myeloid leukemia treatment market size was estimated at USD 3.47 billion in 2024 and is projected to reach USD 6.29 billion by 2030. North America held the largest share of this market, with 37.6% in 2024, and the U.S. market accounted for 90.9% of the North American market.
- Other estimates for the global acute myeloid leukemia treatment market size include USD 3.91 billion in 2025, projected to grow to USD 9.79 billion by 2034.
- The acute myeloid leukemia therapeutics market for second-line/relapsed treatments is forecast to rise at a 13.07% CAGR through 2031.
-
CB-020 for solid tumors:
- The global solid tumors market size was valued at USD 362.21 billion in 2024 and is projected to reach USD 1557.42 billion by 2032. North America currently dominates this market.
- Another report indicates the global solid tumor cancer treatment market size was USD 232.2 billion in 2024 and is expected to grow to USD 442.79 billion in 2029. North America was the largest region in this market in 2024.
- The global solid tumor therapeutics market is expected to grow from USD 207.29 billion in 2025 to USD 326.82 billion by 2031. North America maintained a 42.03% share in 2025.
AI Analysis | Feedback
For Caribou Biosciences (CRBU), a clinical-stage biopharmaceutical company, the expected drivers of future revenue growth over the next 2-3 years are primarily tied to the advancement of its genome-edited cell therapy pipeline and strategic partnerships.
- Progression of CB-010 (vispa-cel) towards pivotal trials: The successful advancement of CB-010, an allogeneic anti-CD19 CAR-T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma, through ongoing discussions with the FDA regarding pivotal trial design and the achievement of subsequent clinical and regulatory milestones, is a significant potential revenue driver. The company expects to provide further updates on Phase 1 data in 2026.
- Advancement of CB-011 (CaMMouflage) through clinical development: Progress in the Phase 1 CaMMouflage trial for CB-011, an allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma, including the reporting of initial dose expansion data and longer follow-up on dose escalation data in 2026, is expected to drive future revenue.
- Establishment of new strategic collaborations and licensing agreements: Caribou Biosciences' current revenue is predominantly generated from licensing and collaboration agreements. Entering into new partnerships or expanding existing ones for its CRISPR technology or pipeline candidates could provide upfront payments, research funding, and milestone payments, thereby boosting revenue growth.
- Achievement of clinical development milestones from existing collaborations: As Caribou's pipeline programs, particularly CB-010 and CB-011, reach pre-defined clinical or regulatory milestones, this is expected to trigger payments from existing partners, contributing to the company's revenue stream. The increase in full year 2025 revenue was primarily attributed to a net increase in revenues related to prior licenses of the company's intellectual property to third parties.
AI Analysis | Feedback
Share Issuance
- In July 2021, Caribou Biosciences completed an initial public offering (IPO), issuing 19,000,000 shares of common stock at $16.00 per share, generating approximately $304.0 million in gross proceeds.
- The company completed a follow-on public offering in 2023, raising $134.4 million.
- Caribou Biosciences raised $25 million through a private placement with Pfizer.
Inbound Investments
- Pfizer made a $25.0 million equity investment in Caribou Biosciences, signifying a strategic stake.
- Caribou Biosciences reported licensing and collaboration revenue, which was $9.994 million in one period, though it decreased by $24.5 million from the previous year, primarily due to the termination of an agreement with AbbVie.
Outbound Investments
- In 2025, Caribou Biosciences recorded a non-recurring, non-cash impairment charge of $21.3 million related to an impairment of its stock investment in a private company.
Capital Expenditures
- For a recent 12-month period, Caribou Biosciences reported capital expenditures of approximately $1.36 million.
- The company's strategic pipeline prioritization and workforce reduction initiatives announced in April 2025 were intended to extend its cash runway into the second half of 2027, implicitly optimizing capital deployment.
- Future capital expenditures are anticipated to include significant funding for the planned vispa-cel pivotal trial, which will require a new funding strategy.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Caribou Biosciences Earnings Notes | 12/16/2025 | |
| Would You Still Hold Caribou Biosciences Stock If It Fell Another 30%? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to CRBU.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 9.30 |
| Mkt Cap | 1.2 |
| Rev LTM | 26 |
| Op Inc LTM | -295 |
| FCF LTM | -263 |
| FCF 3Y Avg | -230 |
| CFO LTM | -255 |
| CFO 3Y Avg | -223 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 14.3% |
| Rev Chg 3Y Avg | 58.8% |
| Rev Chg Q | 78.8% |
| QoQ Delta Rev Chg LTM | 17.6% |
| Op Inc Chg LTM | 17.9% |
| Op Inc Chg 3Y Avg | -5.5% |
| Op Mgn LTM | -463.1% |
| Op Mgn 3Y Avg | -699.4% |
| QoQ Delta Op Mgn LTM | 268.7% |
| CFO/Rev LTM | -495.6% |
| CFO/Rev 3Y Avg | -583.4% |
| FCF/Rev LTM | -497.1% |
| FCF/Rev 3Y Avg | -597.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.2 |
| P/S | 20.8 |
| P/Op Inc | -3.6 |
| P/EBIT | -3.4 |
| P/E | -3.5 |
| P/CFO | -4.0 |
| Total Yield | -29.8% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -36.7% |
| D/E | 0.1 |
| Net D/E | -0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 20.2% |
| 3M Rtn | 33.6% |
| 6M Rtn | -17.9% |
| 12M Rtn | 80.8% |
| 3Y Rtn | -53.4% |
| 1M Excs Rtn | 11.6% |
| 3M Excs Rtn | 29.6% |
| 6M Excs Rtn | -19.5% |
| 12M Excs Rtn | 62.4% |
| 3Y Excs Rtn | -122.9% |
Price Behavior
| Market Price | $2.25 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 07/23/2021 | |
| Distance from 52W High | -20.8% | |
| 50 Days | 200 Days | |
| DMA Price | $1.89 | $1.92 |
| DMA Trend | up | up |
| Distance from DMA | 19.2% | 17.0% |
| 3M | 1YR | |
| Volatility | 76.5% | 88.3% |
| Downside Capture | 0.01 | 1.27 |
| Upside Capture | 376.22 | 321.86 |
| Correlation (SPY) | 33.3% | 33.3% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.64 | 1.88 | 2.00 | 2.58 | 1.64 | 1.78 |
| Up Beta | 1.31 | 1.51 | 3.96 | 1.74 | 1.18 | 1.65 |
| Down Beta | 0.71 | 1.65 | 0.85 | 2.48 | 1.26 | 1.63 |
| Up Capture | 334% | 417% | 352% | 374% | 711% | 428% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 9 | 22 | 30 | 57 | 122 | 333 |
| Down Capture | 128% | 70% | 138% | 213% | 152% | 112% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 13 | 20 | 30 | 64 | 122 | 390 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CRBU | |
|---|---|---|---|---|
| CRBU | 203.0% | 88.6% | 1.65 | - |
| Sector ETF (XLV) | 9.2% | 16.0% | 0.37 | 34.8% |
| Equity (SPY) | 23.7% | 12.7% | 1.52 | 34.2% |
| Gold (GLD) | 41.4% | 27.5% | 1.25 | 10.8% |
| Commodities (DBC) | 22.4% | 16.2% | 1.25 | -0.1% |
| Real Estate (VNQ) | 14.2% | 13.8% | 0.72 | 23.9% |
| Bitcoin (BTCUSD) | -10.4% | 42.7% | -0.14 | 21.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CRBU | |
|---|---|---|---|---|
| CRBU | -32.9% | 87.3% | -0.09 | - |
| Sector ETF (XLV) | 5.9% | 14.6% | 0.22 | 29.3% |
| Equity (SPY) | 10.8% | 17.1% | 0.49 | 36.2% |
| Gold (GLD) | 21.6% | 17.8% | 0.99 | 8.7% |
| Commodities (DBC) | 10.9% | 18.8% | 0.47 | 5.0% |
| Real Estate (VNQ) | 4.1% | 18.8% | 0.12 | 30.7% |
| Bitcoin (BTCUSD) | 3.8% | 56.4% | 0.29 | 22.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CRBU | |
|---|---|---|---|---|
| CRBU | -18.1% | 87.3% | -0.09 | - |
| Sector ETF (XLV) | 9.5% | 16.5% | 0.47 | 29.3% |
| Equity (SPY) | 13.9% | 17.9% | 0.67 | 36.2% |
| Gold (GLD) | 13.7% | 15.9% | 0.71 | 8.7% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 5.0% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.23 | 30.7% |
| Bitcoin (BTCUSD) | 68.0% | 66.9% | 1.07 | 22.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/5/2026 | 6.4% | 10.5% | 14.0% |
| 11/3/2025 | 0.4% | -13.6% | -23.1% |
| 8/12/2025 | 8.9% | -1.1% | 6.7% |
| 3/10/2025 | -3.2% | -7.7% | -28.5% |
| 11/6/2024 | 1.1% | -20.0% | -22.5% |
| 7/16/2024 | -3.3% | -12.1% | -30.4% |
| 3/11/2024 | -30.5% | -27.6% | -39.8% |
| 11/7/2023 | -5.0% | -11.5% | 24.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 5 | 4 |
| # Negative | 6 | 9 | 10 |
| Median Positive | 5.8% | 8.5% | 19.4% |
| Median Negative | -5.5% | -12.1% | -22.3% |
| Max Positive | 14.3% | 32.1% | 46.1% |
| Max Negative | -30.5% | -27.6% | -39.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/05/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/10/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/11/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 3/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Cash Runway | |||||||
Prior: Q3 2025 Earnings Reported 11/12/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Cash Runway | |||||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Haurwitz, Rachel E | President and CEO | Trust | Buy | 3172025 | 1.02 | 20,000 | 20,400 | 3,436,783 | Form |
| 2 | McClung, Barbara G | Chief Legal Officer | Direct | Sell | 2212025 | 1.35 | 3,564 | 4,811 | 598,728 | Form |
| 3 | Khan, Ruhi Ahmad | Chief Business Officer | Direct | Sell | 2212025 | 1.35 | 3,564 | 4,811 | 90,364 | Form |
| 4 | Kanner, Steven | Chief Scientific Officer | Direct | Sell | 2212025 | 1.35 | 3,564 | 4,811 | 582,601 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.